Bill Maughan
Stock Analyst at Canaccord Genuity
(0.05)
# 4,120
Out of 4,711 analysts
14
Total ratings
12.5%
Success rate
-29.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $8.28 | +214.01% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $2.37 | +532.91% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $1.68 | +435.71% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $28.33 | +136.54% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $39.39 | +169.10% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $1.10 | +2,081.82% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $14.68 | +308.72% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $41.85 | +7.53% | 1 | Nov 2, 2023 |
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $8.28
Upside: +214.01%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.37
Upside: +532.91%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.68
Upside: +435.71%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $28.33
Upside: +136.54%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $39.39
Upside: +169.10%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $1.10
Upside: +2,081.82%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $14.68
Upside: +308.72%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $41.85
Upside: +7.53%